What Happened
Advanced Biosynthesis Company Expands Domestic Manufacturing
Antheia, an advanced biosynthesis company, has secured a conditional funding commitment of $80 million from the U.S. Department of War’s Office of Strategic Capital. The financing will support Antheia’s domestic manufacturing strategy, aiming to onshore production of critical pharmaceutical ingredients and reduce reliance on foreign suppliers. This move is seen as a step towards securing public health and national security, as the U.S. currently relies heavily on foreign countries for key starting materials and active pharmaceutical ingredients. According to Antheia, this funding commitment was reported by the company itself.